NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today ...
Syndax Pharmaceuticals reported strong early results for its newly launched products, achieving $7.7 million in net revenue from Revuforj® (revumenib) in just five weeks following its U.S. launch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback